Incyte EVP files initial insider ownership: 67k shares reported
Rhea-AI Filing Summary
Form 3 filing snapshot: On 21 Jul 2025 Patrick A. Mayes—newly appointed EVP & Chief Scientific Officer of Incyte Corp. (INCY)—submitted his initial statement of beneficial ownership.
- Direct equity: 67,388 common shares, the bulk of which are restricted stock units scheduled to vest between 2025-2028.
- Derivative exposure: 57,080 employee stock options across 15 grants; strike prices range from $61.18 to $106.47 with expirations from 2027-2035. Most awards are either fully vested or vest monthly/annually over four years.
The filing establishes Mayes as a Section 16 insider and documents equity-based incentives that align his compensation with shareholder value. No purchases or sales occurred, so immediate market impact is minimal.
Positive
- Executive ownership of 67,388 shares and 57,080 options indicates meaningful equity alignment with shareholders.
Negative
- None.
Insights
TL;DR: Routine Form 3; new EVP discloses sizeable equity stake—governance compliance, low market impact.
This initial filing simply brings Patrick A. Mayes under Section 16 reporting following his promotion. The combined 67 k shares and 57 k options represent a meaningful personal stake but do not alter the firm’s capitalization. Strike dispersion (≈$61–$106) suggests upside-weighted incentives. Because there are no open-market transactions, the disclosure is informational rather than directional for investors.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (9)
- F1. This includes: 3,533 restricted stock units ("RSUs") granted on October 1, 2021 that will vest fully on October 1, 2025; 1,128 RSUs granted on July 2, 2022 that will fully on July 2, 2026; 3,079 RSUs granted on January 20, 2023 that will vest fully on January 20, 2027; 2,820 RSUs granted on July 14, 2023 that will vest 1,140 on July 14, 2026 and July 14, 2027; 5,253 RSUs granted on July 15, 2024 that will vest 1,751 on July 15, 2026, July 15, 2027 and July 15, 2028; 39,783 RSUs granted on June 6, 2025 that will vest fully on June 6, 2028; and 7,795 RSUs granted on July 15, 2025 that will vest 25% annually over four years.
- F2. As of July 21st, 2025, the award is fully vested and exercisable
- F3. Options granted on July 2, 2022 and will vest monthly through July 2, 2026
- F4. Options granted on January 20, 2023 and will vest monthly through July 2, 2026
- F5. Options granted on July 14, 2023 and will vest monthly through July 14, 2027
- F6. Options granted on January 18, 2024 and will vest monthly through July 14, 2027
- F7. Options granted on July 15, 2024 and will vest monthly through July 15, 2028
- F8. Options granted on January 17, 2025 and will vest monthly through July 15, 2028
- F9. Options granted on July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
